366 Index Name Paper ref. Name Paper ref. Schoeberl, B FC07.1.4 Schoedel, K Wed 193 Scholten, D Thu 060 Schömig, E Mon 315 Schöneberg, T Thu 087 Schönfeld, D Tue 211 Schramm, TK FC04.2.4 Schratz, M Mon 479, Thu 354 Schreiber, G Wed 410 Schrey, D FC10.4.5 Schrier, L Thu 214, FC10.4.6 Schröder, R FC11.1.6 Schroth, W Wed 133 Schubert, B Mon 479 Schuelein, R Thu 095 Schuemie, M FC04.1.6 Schul, W W31.2 Schulpis, K Tue 381 Schultz-Larsen, P Wed 160 Schulz, A FC18.2.6 Schulz, G Tue 099 Schulz, R W22 Schulz, S Tue 219 Schuur, LJ Wed 095 Schwab, M YI.02, FC02.1.5, Wed 133 Schwab, M PL07 Schwappach, D Tue 108 Schwartz, A Wed 126 Schwartz, T Thu 037 Schwartz, TW FC11.1.2, Thu 036 Schwarz, U Tue 301, FC02.1.6 Schwarz, Ute Tue 054 Sciulli, MG Mon 281 Scotti, L Tue 093 Scuderi, C Tue 465, FC18.4.6 Se, Y Tue 090 Sederino, R Tue 454 Sediki, M Tue 289, Tue 290 Sedivý, J Mon 267 See, HB Wed 079 Seeanner, M Wed 280, Wed 210, Thu 252 Seeger-Armbruster, S Mon 463 Seeman, P Wed 443 Seeringer, A W16.5, Mon 315, Wed 148, Thu 112 Segarceanu, A Mon 111 Segarra, G Thu 225 Segi-Nishida, E Tue 260 Segura, V Thu 050 Seidenbusch, W Mon 479, Thu 211, Thu 354, Mon 245 Seif el-Din, S Mon 372 Seiwerth, S W02.3.1 Seki, A Tue 380 Sekiguchi, F FC03.2.5, Mon 243, Mon 250, Tue 263 Sekijima, M FC13.2.5 Sekine, M Tue 379, Tue 177 Selbach, O W33.3 Selemidis, S Mon 305, FC15.1.4 Selent, J YI.03 Selimovic, A Wed 171 Selke-Krulichova, I Wed 017 Sellers, E Wed 193 Selley, DE Wed 029 Seltzman, H Thu 021 Selvam, C FC11.3.6 Sen, D Tue 120 Senbel, A Tue 208, Tue 264 Sendo, T Wed 413 Sengupta, A Wed 149, Thu 113 Seniuk, J Mon 095, Mon 097, Mon 094 Senn, N Thu 211, Thu 354 Senn, T Tue 099 Seo, D FC14.3.3 Seo, S-K Tue 427 Seong, YH Wed 276, Wed 416, Wed 427 Sepehr- Ara, L Thu 100 Sepehri, H Mon 455 Sepehrizadeh, Z Mon 454 Serebrova, S Thu 114, Wed 314 Seredenin, SB Mon 431, Thu 415, Wed 248, Mon 225, Wed 188, Tue 276 Tue 150, Tue 165, Wed 187 Serfontein, J Mon 026 Sergeeva, O W33.3 Sergeeva, SA Mon 198, Mon 284, Thu 015 Sergienko, A Tue 472 Serra, CSM Wed 144 Serrano Lopez, DR Thu 115 Serrão, MP Thu 398, Wed 114 Sertiæ, J Mon 048 Sertic, D Tue 304 Sertic, J Tue 304 Sestan, B Tue 095 Sesti-Costa, R W31.3 Seta, F Wed 235 Seto, SW Wed 236 Sevior, D Thu 348 Sexton, P Thu 080 Sexton, PM Wed 089, Wed 082, Wed 043 Thu 041 Seya, K Tue 430 Seyedian, R Tue 017, Sezer, Zafer Tue 018 Sfaxi, L Mon 338 Shaban, G FC06.2.6 Shabbi, H Thu 002 Shafiee, A Thu 309 Tue 469 Shah, A Thu 197 Shah, T FC16.1.6 Shaham, Y FC14.3.2, FC14.3.4 Shaikh, NA Thu 338 Shakib, S Tue 327 Shalamai, A FC06.1.6 Sham, PC Mon 271, Mon 159 Shamsabadi, RH Thu 006 Shamseddin, A FC01.3.4 Shang, F FC08.1.6 Shao, Z Thu 388 Shapovalov, G Wed 102 Sharifi, M Wed 376, Tue 469 Sharma, K Tue 453, Tue 019, Tue 019 Sharma, KK Tue 020, Wed 116 Sharma, L Mon 131, Wed 116 Sharma, LK Tue 453, Tue 020, Tue 019 Sharma, M Tue 137 Sharma, P FC09.5.5
Name Paper ref. Name Paper ref. Sharma, S FC09.5.5, FC05.2.5 Sharman, JL Tue 479 Sharp, T PL03 Sharyari, S Wed 027 Shaw, F-Z Mon 456 Sheikh, S FC06.2.5 Sheikh, SP Wed 070, Wed 036 Shelihova, L Tue 106 Shelton, J Wed 093 Shen, F-M Mon 322 Shen, WW Wed 430 Shen, Y Tue 138, Mon 457, Thu 445, Thu 089 Shen, Y Tue 138, Mon 457, Mon 458 Shen, Z Tue 139 Sheng, L Wed 336 Sheppard, J Thu 110 Sheu, J-R Mon 423 Shevtsov, V Mon 134 Sheykhzade, M Thu 066, Mon 099 Shi, J-S FC14.4.6, Tue 182, Thu 184, Tue 382, Tue 178, Thu 185, Thu 186 Shi, J-Z Thu 116, Tue 458 Shi, L FC02.1.2 Thu 384, FC02.3.5, Mon 073 Shi, M Tue 228, Wed 122, Wed 121, Wed 120 Shiba, T Tue 376 Shibasaki, H Tue 159 Shibasaki-Hirano, H Mon 459 Shibata, K Wed 256, Thu 117 Shibata, M Tue 156 Shibata, S Mon 173, Tue 122, Thu 416 Shibayama, H Tue 077 Shibuya, A Tue 265 Shibuya, K Tue 166 Shibuya, M Thu 286 Shih, Y-T Thu 301 Shiiya, T Wed 060 Shiiya, T Tue 140 Shikh, E Thu 349 Shimada, S Wed 305 Shimamoto, N Tue 379, Tue 177 Shimane, T Thu 416 Shimazawa, M Thu 220, Thu 406 Shimizu, M Tue 474 Shimizu, Y Mon 178 Shimoda, M Mon 173 Shimokawa, H FC16.1.4 Shimuta, S Thu 025 Shimuta, SI Wed 041, Thu 061 Shin, Heung Thu 350 Shin, J-G Tue 352, Tue 351 Shin, MC Wed 371 Shin, S Mon 029 Shinohara, M Tue 266 Shinozuka, K Thu 320, Tue 143, Tue 067 Shintani, N Wed 075, Mon 110, Mon 318 Shioda, N Thu 406 Shipaeva, E Tue 276, Shipovskaya, N Tue 106 Shippenberg, T FC03.3.1 Shiraishi, F Tue 162 Shirakawa, H Tue 055 Shirinbeik Mohajer, O Mon 196 Shohin, IE Thu 253 Shohreh, R Mon 105, Wed 434, Wed 329 Shoji, M Wed 061, Mon 179 Shokrgozar, MA Wed 437 Shono, M Tue 068 Short, J Tue 215 Shrivastava, AK Wed 315 Shujaa, N W19.1, Thu 062, Thu 094 Shukitt-Hale, B Mon 443 Shukuri, M Tue 244 Shumkova, O Thu 349 Shweta, Wed 444 Sia, I Thu 334 Sibley, D Thu 063 Siddika, MM Mon 001 Siddiqi, HS Wed 355 Siddique, MW Tue 137 Siddiqui, S Tue 119 Siderius, M Wed 086 Siderius, N Thu 085 Sidhu, P Tue 191 Siegmund, W Tue 045, Tue 049, Tue 039, Wed 119, Tue 041 Siegrist, J Wed 170 Sierra, PP Mon 038 Siest, J-P Mon 369 Siew Hua, G Mon 147, Mon 333 Sigrist-Flores, SC Tue 150 Sikiric, P W02.3.1 Silber, H FC07.2.2 Siller, M Thu 118 Silva, AP Wed 180, Thu 193 Silva, BA Thu 351, Thu 352 Silva, D Thu 119 Silva, E Mon 350 Silva, F Tue 123 Silva, I FC08.2.6, Thu 064, Tue 207 Silva, J Wed 212, Wed 265, Wed 140 Silva, JA Mon 295 Silva, JJN W31.3 Silva, JLV Thu 351, Thu 352 Silva, J Thu 254 Silva, L Mon 398 Silva, MAS Wed 342 Silva, MS Thu 352 Silva, TMS Thu 351 Silva, WL Wed 144 Silva-Lima, B Tue 207 Silva-Ramos, M FC08.2.6 Sim, HL Thu 181 Sim, SC Wed 151 Sim, TF Tue 063 Simaan, J Mon 396 Simard, G Tue 118 Simatupang, A Tue 009, Tue 021 Simic, D Tue 108 Simmonds, M FC16.5.2 Simms, J FC14.3.5, Wed 057, Wed 082, FC14.2.3 Sa, Z Thu 400 Seau, G Tue 188, Tue 189 Set, S Thu 273, Thu 274 Index 367
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299:
FC15 Endothelium in health and dise
- Page 300 and 301:
FC15 Endothelium in health and dise
- Page 302 and 303:
FC15 Endothelium in health and dise
- Page 304 and 305:
FC16 Natural products: Past and fut
- Page 306 and 307:
FC16 Natural products: Past and fut
- Page 308 and 309:
FC16 Natural products: Past and fut
- Page 310 and 311:
FC16 Natural products: Past and fut
- Page 312 and 313:
FC17 New approaches and targets in
- Page 314 and 315:
FC18 Nuclear receptor targets for t
- Page 316 and 317:
314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor